Co-Aggregation of Alpha-Synuclein with Amylin(HIAPP) Leads to an Increased Risk in Type ii Diabetes Patients for Developing Parkinson's Disease

Yoav Atsmon-Raz; Yifat Miller

doi:10.1016/j.bpj.2014.11.2872

Co-Aggregation of Alpha-Synuclein with Amylin(HIAPP) Leads to an Increased Risk in Type ii Diabetes Patients for Developing Parkinson's Disease

Yoav Atsmon-Raz, Yifat Miller

Department of Chemistry

Ben-Gurion University of the Negev

Research output: Contribution to journal › Meeting Abstract

Abstract

Clinical studies have reported that Type II diabetes patients (T2D) are more
likely to develop Parkinson’s disease (PD). However, the mechanisms which
link these two diseases have remained elusive. In T2D, Amylin forms aggregates in the pancreas. However, it can also form neurotoxic oligomers in the brain.

Original language	American English
Pages (from-to)	524A-524A
Number of pages	1
Journal	Biophysical Journal
Volume	108
Issue number	2
DOIs	https://doi.org/10.1016/j.bpj.2014.11.2872
State	Published - Jan 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.bpj.2014.11.2872

Cite this

@article{1f9fe7ea0c51492da4dcacd694b421bd,

title = "Co-Aggregation of Alpha-Synuclein with Amylin(HIAPP) Leads to an Increased Risk in Type ii Diabetes Patients for Developing Parkinson's Disease",

abstract = "Clinical studies have reported that Type II diabetes patients (T2D) are morelikely to develop Parkinson{\textquoteright}s disease (PD). However, the mechanisms whichlink these two diseases have remained elusive. In T2D, Amylin forms aggregates in the pancreas. However, it can also form neurotoxic oligomers in the brain.",

author = "Yoav Atsmon-Raz and Yifat Miller",

year = "2015",

month = jan,

doi = "10.1016/j.bpj.2014.11.2872",

language = "American English",

volume = "108",

pages = "524A--524A",

journal = "Biophysical Journal",

issn = "0006-3495",

publisher = "Elsevier B.V.",

number = "2",

}

TY - JOUR

T1 - Co-Aggregation of Alpha-Synuclein with Amylin(HIAPP) Leads to an Increased Risk in Type ii Diabetes Patients for Developing Parkinson's Disease

AU - Atsmon-Raz, Yoav

AU - Miller, Yifat

PY - 2015/1

Y1 - 2015/1

N2 - Clinical studies have reported that Type II diabetes patients (T2D) are morelikely to develop Parkinson’s disease (PD). However, the mechanisms whichlink these two diseases have remained elusive. In T2D, Amylin forms aggregates in the pancreas. However, it can also form neurotoxic oligomers in the brain.

AB - Clinical studies have reported that Type II diabetes patients (T2D) are morelikely to develop Parkinson’s disease (PD). However, the mechanisms whichlink these two diseases have remained elusive. In T2D, Amylin forms aggregates in the pancreas. However, it can also form neurotoxic oligomers in the brain.

U2 - 10.1016/j.bpj.2014.11.2872

DO - 10.1016/j.bpj.2014.11.2872

M3 - Meeting Abstract

SN - 0006-3495

VL - 108

SP - 524A-524A

JO - Biophysical Journal

JF - Biophysical Journal

IS - 2

ER -